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Aim: The aim was to evaluate the cost–effectiveness of endoscopic eradication 
therapy (EET) with combined endoscopic mucosal resection and radiofrequency 
ablation for the treatment of high-grade dysplasia (HGD) arising in patients with 
Barrett’s esophagus compared with endoscopic surveillance alone in the UK. Materials 
& methods: The cost–effectiveness model consisted of a decision tree and modified 
Markov model. A lifetime time horizon was adopted with the perspective of the UK 
healthcare system. Results: The base case analysis estimates that EET for the treatment 
of HGD is cost-effective at a GB£20,000 cost–effectiveness threshold compared with 
providing surveillance alone for HGD patients (incremental cost–effectiveness ratio: 
GB£1272). Conclusion: EET is likely to be a cost-effective treatment strategy compared 
with surveillance alone in patients with HGD arising in Barrett’s esophagus in the UK.
First draft submitted: 6 December 2016; Accepted for publication: 10 March 2017; 
Published online: 25 May 2017
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Barrett’s esophagus (BE) is a precancerous 
state that can develop into esophageal adeno-
carcinoma (OAC). BE exists in most patients 
in a metaplastic state and carries a very low 
risk of progression to invasive neoplasia and 
OAC in the region of 0.12–0.5% per year [1,2]. 
The 2013 British Society of Gastroenterol-
ogy (BSG) guidelines advise that, in those 
patients with BE in whom there is no neo-
plasia, surveillance is recommended for those 
fit for endoscopy [3]. This is based on existing 
evidence from published studies which show 
that surveillance correlates with early-stage 
cancer diagnosis and likely improved survival 
from other cancers [4–6]. Recent work from 
the ProBar study group examined data from 
the Dutch cancer registry. They compared 
survival of patients with BE with neoplastic 
progression during surveillance with those of 
patients without neoplastic progression and 
patients with OAC in the general population. 
They found that OAC was diagnosed at an 
earlier stage during BE surveillance than in 
the general population. However, the survival 
of patients with BE with neoplastic progres-
sion was not significantly worse than those 
of patients without neoplastic progression, 
and was similar to survival of patients with 
stage 0 or stage 1 OAC in the general popula-
tion [7]. In patients with OAC, the prognosis 
is poor with just over 15% patients being alive 
at 5 years [8].
Current UK surveillance guidelines [3] 
recommend that patients with BE undergo 
endoscopy every 2–5 years. In some patients, 
no surveillance is recommended due to the 
negligible risk for cancer progression. The 
intervals are dependent on the length of BE 
and presence of intestinal metaplasia at the 
index endoscopy. However, in a minority 
of patients with BE there is a molecular and 
pathological transformation through various 
dysplastic stages to mucosal dysplasia and can-
cer and then finally invasive disease where it 
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Figure 1. Model Structure (see facing page). (A) Model structure – treatment arm. The model structure consists of 
an initial decision tree, in which HGD patients enter the model in the treatment arm and were assumed to have EET. 
This determines which health state they moved into in the Markov component. After initial treatment all patients 
enter the natural history Markov model. Patients could move between health states as shown in the diagram 
(NDBE, LGD, HGD and OAC). Patients in both NDME and LGD receive surveillance and patients in HGD received EET. 
Patients with OAC undergo esophagectomy. (B) Model structure – comparator arm. The model structure consists of 
Markov model in which HGD patients enter the model in the comparator arm. All patients enter the natural history 
Markov model. Patients could move between health states as shown in the diagram (NDBE, LGD, HGD and OAC). 
Patients in both LGD and HGD receive surveillance. Patients with OAC undergo esophagectomy. 
EET: Endoscopic eradication therapy; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; NDBE: Nondysplastic 
Barrett’s esophagus; OAC: Esophageal adenocarcinoma. 
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is desirable to treat early. High-grade dysplasia (HGD) 
and intramucosal cancer (IMC) (collectively referred to 
as BE-related neoplasia), arising from BE can carry a 
40–60% risk of progressing to OAC [9]. In some series, 
the risk of patients with HGD in BE progressing to 
OAC is 16–59% within 5 years of diagnosis [10].
Traditionally, esophagectomy has remained the 
mainstay of managing those patients with early muco-
sal neoplasia in BE. This is not only because of the 
significant risk of progression to OAC but also because 
up to 40% of patients with HGD may already harbor 
occult cancer in the Barrett’s segment [11], although 
subsequent studies suggest this rate is much lower [12]. 
Even in specialist high-volume centers this operation 
carries a high mortality rate of 2–5% and subsequent 
morbidity of up to 40% [13,14]. Recent data from the 
National Oesophago-Gastric Cancer Audit (NOGCA) 
in the UK, indicated that 30-day mortality was 2.2% 
and there were significant postoperative complications 
and long-term morbidity in 40% of patients [15,16].
The introduction of minimally invasive endotherapies 
such as photodynamic therapy (PDT), radiofrequency 
ablation (RFA), cryotherapy and endoscopic mucosal 
and submucosal resection (EMR and ESD) over the past 
decade have seen a paradigm shift in the management 
of patients with BE-related neoplasia. Maximally inva-
sive treatment for early esophageal cancer with esopha-
gectomy continues to carry a significant mortality and 
morbidity. Surgery was previously reserved for patients 
with HGD or IMC arising in BE. As a result there has 
been a major emphasis toward targeting patients who 
are at risk of developing OAC, to try and intervene at 
a preneoplastic and early cancer stage of the aggressive 
disease process to improve outcomes.
In 2010 the UK National Institute for Health and 
Care Excellence (NICE), published guidelines on the 
use of RFA in HGD in BE. Subsequently, RFA and 
EMR are now NICE-approved treatments for HGD 
and IMC arising in BE. In 2013, the BSG [3] endorsed 
the use of minimally invasive endoscopic treatment 
for early Barrett’s neoplasia, together with combined 
endoscopic resection for lesions, followed by ablation 
with radio frequency. The American Gastroentero-
logical Association and American College of Gastro-
enterology also support this approach to patients with 
BE-related neoplasia over surveillance or surgery with 
esophagectomy [17,18].
Societies worldwide now endorse the use of mini-
mally invasive endoscopic therapy with endoscopic 
resection of visible lesions followed by RFA to treat 
patients with BE-related mucosal neoplasia [3,18]. The 
2013 BSG guidelines advise that, for HGD arising 
in patients with BE that is confined to the mucosa, 
endoscopic therapy is preferred over esophagectomy or 
endoscopic surveillance. The use of endoscopic resec-
tion is considered to be the therapy of choice for dys-
plasia associated with visible lesions and T1a neoplasia. 
In the presence of HGD without visible lesions, these 
patients should be managed with an endoscopic abla-
tive technique with the majority of the recent evidence 
base favoring the use of RFA. Several large volume 
studies have shown high rates of disease eradication 
with RFA in patients with HGD arising in BE [19–22]. 
The cost–effectiveness for endoscopic therapy for BE 
neoplasia remains an area of debate [16].
Cost–effectiveness analysis is used by decision mak-
ers to determine the allocation of scare resources. In 
cost–effectiveness analysis health outcomes are often 
measured using quality-adjusted life years (QALYs). 
This measure uses ‘utility’ – a scale in which health is 
measured from 0 to 1, with 1 being perfect health and 
0 being dead or equivalent to being dead. The util-
ity score is multiplied by the amount of time a patient 
spends in that health state and so accounts for both 
quality and quantity of life. The preferred method of 
presenting cost–effectiveness results is the incremen-
tal cost–effectiveness ratio (ICER), this ratio takes 
into account the extra cost and the extra benefit (in 
this case QALYs). An intervention can be considered 
cost-effective if the benefits gained are greater than 
the opportunity costs. ICERs under GB£20,000 up to 
GB£30,000 are usually considered to be ‘cost-effective’ 
in the UK [23].
This is the first UK study to evaluate the cost–
effectiveness of endoscopic treatment of BE neoplasia 
versus endoscopic surveillance in a cohort of patients 
with HGD in BE. Previous UK studies in the same 
patient cohort have compared different treatment 
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options in practice at the time (e.g., esophagectomy 
for HGD) [24].
The aim of this study was to evaluate the cost–
effectiveness of endoscopic eradication therapy (EET) 
for the treatment of HGD in BE patients compared 
with endoscopic surveillance alone in the UK.
Materials & methods
The economic model was developed from the perspec-
tive of the National Health Service (NHS) and per-
sonal social services. The model adopted a lifetime time 
horizon; annual discount rates of 3.5% were applied to 
costs and benefits, as per the NICE reference case [23]. 
An annual cycle length was used in the model. A hypo-
thetical cohort of BE patients following an initial diag-
nosis of HGD was modeled. In the intervention (EET) 
arm, patients with HGD were treated with EET. In the 
comparator arm, patients with HGD received surveil-
lance only until esophageal cancer developed. In both 
arms, patients with no dysplasia Barrett’s esophagus 
(NDBE) or low-grade dysplasia (LGD) were assumed 
to have surveillance.
Model structure
The model structure is outlined in Figure 1A & B. The 
model structure consists of an initial decision tree, in 
which patients in the treatment arm were assumed to 
have EET. This determines which health state they 
moved into in the Markov component. After initial 
treatment all patients enter the natural history Mar-
kov model. Patients could move between health states 
as shown in the diagram (NDBE, LGD, HGD and 
OAC). In the treatment arm, when patients were ‘new’ 
to HGD, they went on to have EET. A patient was con-
sidered ‘new’ to a health state when they were not there 
in the last cycle of the model. For example, a patient 
could undergo EET at the start of the model and enter 
NDBE, they could then progress to LGD then HGD 
where they would be given RFA treatment again. As 
such, dependent on the treatment outcome, the patient 
re-enters the natural history section either in the health 
state they were in when they had treatment if the dys-
plasia was not eradicated, or NDBE. Patients who were 
not being treated underwent surveillance. If a patient 
progressed to OAC, they underwent an esophagectomy 
and the outcome of this treatment was either ‘cured’ 
with a lifelong lower quality of life (QOL) [13,14] or the 
patient dies. Costs and utilities were assigned to the 
number of patients in each health state.
Model inputs 
Effectiveness
Effectiveness inputs were derived from published lit-
erature and were used in both arms of the model 
(although applied slightly differently, as illustrated 
in Figure 1A & B). Three studies were identified that 
reported transition probabilities [25–27]. Many of the 
inputs reported were the same or similar. Das et al. [27] 
had some data missing (probability of movement from 
LGD to NDBE and LGD) necessary to populate the 
transition probability matrix. However, these data were 
mostly taken from Shaheen et al. [25] which is considered 
separately. Therefore, the options included in the model 
were two sets of probabilities from Inadomi et al. [26] 
and one from Shaheen et al. [25]. Inadomi et al. was 
selected for the base case input because this was the 
most up-to-date. In addition, Inadomi et al. carried out 
an analysis in which they altered the absolute values 
(based on the proportional relationships between tran-
sitions) to fit overall cancer incidence statistics. Inputs 
and sources are summarized in Table 1.
Cost
The unit costs in the model were derived from 
standard costs sources used in the UK (outlined in 
Table 1). The resource use was drawn from a variety 
of sources. Costs were limited to direct healthcare 
costs. Costs were calculated based on an annual cycle 
length. For NDBE, one surveillance session every 
3–5 years was assumed, two sessions per year for 
LGD and three sessions per year for HGD, though 
this cost was only applied in the comparator arm in 
which HGD patients were not receiving treatment (a 
scenario analysis was carried out with four sessions per 
year for HGD). Drugs costs consisted of the average 
cost of acid suppression during and after the treatment 
phase with proton pump inhibitors (PPIs; omeprazole, 
lansoprazole, rabeprazole, pantoprazole and esome-
prazole) [31]. Further to clinical expert advice, the dose 
was doubled for patients who were undergoing endo-
scopic treatment. The cost of double the dose of PPIs 
and H2 antagonist drugs was applied for 12 months 
following EET.
Quality of life
BE utilities were identified from published litera-
ture [29] (Table 1). However, the calculations used in 
the NICE model were based on a utility score of 1 
for no BE. A utility of 1 represents perfect health, 
which is unlikely to be a realistic estimate. Instead, 
the average utility for a population of this age was 
included from the EuroQOL population norms [32]. 
The disutility that was applied to the utility value of 
1 in the NICE guidance was applied to the EuroQOL 
population average instead. Additionally, disutility 
values were applied when any of the following events 
occurred: stricture, surgery for perforation, EET, 
esophagectomy surgery.
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Table 1. Model inputs used in the base case.
Parameter Base case Notes Ref.
Effectiveness inputs 
Success of RFA for HGD: 
– Complete eradication of dysplasia 92.6%  – [28]
– Residual dysplasia 7.4%  – [28]
– Natural history transition probabilities Full table available in reference  – [26]
Cost inputs
RFA GB£1509 per session Average number of treatments = 3 [29,30]
EMR GB£702 per session Average number of treatments = 1 [29,30]
Stricture GB£3931 Average number of sessions to treat 
stricture is 1.3 (average) endoscopies 
and dilatations
[19,29–30]
Perforation GB£7807 Cc score of 2–3. 6-day stay [30]
Esophagectomy GB£9678 Excess bed days included. Total stay 
12 days
[29,30]
Surveillance GB£681 And expert opinion [30]
PPI drug costs Average annual cost = GB£61 – [31]
PPI additional following surgery GB£61 – [31]
H2 antagonist drugs following surgery GB£444.69 – ranitidine – [31]
Utility inputs
Cured (or no Barrett’s esophagus) 0.80  [32]
NDBE 0.71 Calculated from the disutilities used in [29]
LGD 0.65 Calculated from the disutilities used in [29]
HGD 0.57 Calculated from the disutilities used in [29]
OAC 0.48 Calculated from the disutilities used in [29]
Cured – postesophagectomy 0.774 Calculated from [26]
Stricture -0.03 (applied for 0.25 months) Calculated from [29]
Surgery for perforation -0.28 (applied for 0.5 months) Calculated from [29]
EMR and RFA surgery -0.06 (applied for 0.5 months) – [24]
Esophagectomy surgery -0.26 (applied for 9 months) Calculated from [29]
Safety inputs
Rate of stricture in RFA procedure 9%  – [19]
Rate of perforation in RFA procedure 0.1% Clinical expert opinion –
Mortality from esophagectomy 4.3%  – [16]
All-cause mortality Dependent on starting age and 
cycle in the model
– [33]
EMR: Endoscopic mucosal resection; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; NDBE: No dysplasia Barrett’s esophagus; OAC: Esophageal 
adenocarcinoma; PPI: Proton pump inhibitor; RFA: Radiofrequency ablation.
Outcomes
The primary outcome of the economic model was the 
ICER based on the total costs and QALYs for each arm. 
The additional cost per extra unit of health benefit 
gained is of key interest to policy and decision-makers. 
ICERs were calculated as follows:
The standard cost–effectiveness threshold used by 
NICE is GB£20,000–30,000, that is, an ICER below 
this threshold is considered ‘cost-effective’ [23].
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Sensitivity analysis
Univariate sensitivity analysis was performed on key 
variables in the model. All input parameters were var-
ied widely, between at least ±50%. Probabilistic sensi-
tivity analysis (PSA) was also undertaken, exploring the 
impact upon the results when varying all parameters 
within the model. PSA involves specifying a probability 
distribution for each parameter. The model then draws 
a number from each input’s individual distribution 
and, for each iteration, a result is generated. The type 
of distribution applied for each input is summarized in 
Table 2. Due to a lack of data, the majority of standard 
errors applied were assumptions. However, an approxi-
mation of the standard errors for the cost of EMR was 
derived from the interquartile ranges reported in NHS 
reference costs [30] and the α and β for the effectiveness 
inputs were derived from the trial [28].
Results 
Base case results
The model estimates that EET for HGD patients is 
cost-effective at a GB£20,000 threshold compared with 
providing surveillance alone. The disaggregated results 
are shown in Table 3. The results show that although 
there are additional costs associated with RFA at a 
30-year time horizon, the QALYs accrued offset this 
additional cost with an estimated ICER of GB£1272. 
This translates to a net health benefit of 0.92 QALYs. 
Net health benefit is the value of the benefit minus the 
costs. Here it is the incremental QALYs minus the total 
costs divided by a GB£20,000 threshold (the health 
expected to be forgone elsewhere).
The results show the ‘per patient’ cost of each health 
state. These costs take into account the number and the 
time spent in each health state. The health state costs 
consist of the cost of surveillance and the cost of drugs. 
The costs relating to EET have been separated out for 
clarity. These costs include the cost of EMR, RFA, 
complications associated with RFA and any additional 
drugs that are prescribed as a result of RFA. It should 
be noted that these costs are incurred in the HGD 
health state explaining why the average per patient cost 
in HGD in the treatment arm is not higher.
Figure 2A shows the Markov cohort trace for the 
treatment and Figure 2B for the comparator arm. The 
Markov cohort trace helps to visualize the movement 
of patients through a fairly complex model structure.
Figure 2A shows that in the treatment arm patients 
are progressing more slowly (some of them have treat-
ment and move back to NDBE where they re-enter 
the natural history model). Initially this is positive, 
because fewer patients are in the more serious health 
states in which higher costs are incurred and in which 
the patient has lower utility. However, because patients 
are progressing through the model more quickly in 
the comparator arm, more patients are undergoing 
esophagectomy. For the patients that undergo esopha-
gectomy, the only outcomes are death, which incurs 
no cost and no utility or ‘cured’ in which no costs are 
incurred but the patient has a lower lifetime utility. 
While these patients are not incurring any costs (but 
are incurring reduced utility), patients in the treat-
ment arm are continuing in the natural history model, 
incurring treatment costs and disutility associated with 
adverse events.
Figure 2B shows the Markov trace for the com-
parator arm. In the comparator arm, patients are 
progressing more quickly through the natural history 
model and there are more people in the ‘cured’ and 
‘dead postesophagectomy’ because patients progress 
through the health states faster. There are also far 
more patients with HGD compared with the treat-
ment arm in which more patients spend time in the 
NDBE health state.
Univariate sensitivity analysis
Extensive univariate sensitivity analyses have been car-
ried out in which one parameter within the model is 
varied in isolation to assess its impact on the model’s 
results. Sensitivity analyses that have a significant 
Table 2. Distributions applied to each parameter in probabilistic sensitivity analysis.
Parameter Distribution
Utilities β
Disutilities (QALYs lost) γ
Costs γ
Safety β
Effectiveness
HGD: No residual dysplasia β
Multiplier NDBE, LGD, HGD Lognormal
HGD: High-grade dysplasia; LGD: Low-grade dysplasia; NDBE: No dysplasia Barrett’s esophagus; QALY: Quality-adjusted life year. 
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impact on the model results (i.e., the ICER increased 
over GB£20,000) are reported here.
Figure 3A shows that, intuitively, as the propor-
tion of patients who have residual dysplasia following 
treatment for HGD is decreased (treatment is more 
effective) the ICER increases.
Figure 3B shows that as the HGD multiplier is 
increased (more people stay in the HGD state each 
cycle) the ICER decreases. When the multiplier is 
applied it changes the transition probability values (the 
probability of patients moving between health states in 
each cycle). When the HGD multiplier is increased, 
the probability of staying in HGD each cycle increases 
and the probability of staying in all the other health 
states is reduced proportionally. The graph levels out 
due to the proportion staying in HGD reaching 100%.
A scenario analysis was carried out in which ongo-
ing costs were applied to patients postesophagectomy. 
This was not included in the base case due to a lack of 
data with which to populate this parameter. However, 
in the scenario analysis an assumption was applied that 
patients incur costs of GB£500 every year, for life after 
esophagectomy. As expected, the results showed that a 
higher cost associated with esophagectomy results in a 
lower ICER. The results of this scenario analysis did 
not change the direction of results.
A further scenario analysis was carried out in which 
the number of surveillance appointments in patients 
with HGD was increased from three per year to four 
per year. The results showed that the costs increased in 
the comparator arm for HGD patients. This resulted 
in a cost saving and, therefore, a dominant ICER.
Probabilistic sensitivity analysis
A visual inspection of a graphical representation of 
the mean of the estimates showed that reasonable sta-
bility in the estimates had been achieved by 2000 iter-
ations; 65% of iterations were cost-effective using a 
GB£20,000 threshold, and 67% using a GB£30,000 
threshold (Figure 4).
Discussion
Our analysis estimates that treating patients with BE 
and HGD with EET compared with endoscopic sur-
veillance alone is cost-effective from a UK healthcare 
perspective. The results are in line with the findings 
of previous similar studies [24,26,34]. However, this is 
the first UK study to evaluate the cost–effectiveness 
of EET versus endoscopic surveillance in a cohort of 
HGD patients. The main aims of this study were to 
reflect current BSG recommendations for treating 
HGD with EET [3] and address the gap identified 
in the 2015 NOGCA [16] which suggested that over 
a quarter of patients with HGD were managed with 
surveillance alone.
Previous studies have been carried out from the US 
healthcare perspective, in which practice and resource 
use is likely to differ from the UK [26,34]. Previous UK 
studies in the same patient cohort have compared differ-
ent treatment options in practice at the time (e.g., esoph-
agectomy for HGD) [24], but this is no longer standard 
practice in the UK as evidenced by recent audit data 
showing that surgery for patients with HGD is performed 
only in a small minority of patients (6.3%) [16].
Univariate sensitivity analysis identified the key 
areas of uncertainty that were likely to affect the direc-
tion of results. The first parameter identified was the 
proportion of patients who had residual dysplasia fol-
lowing RFA treatment. The data input for this value 
was derived from a single landmark randomised con-
trol trial (RCT) of 119 patients with BE-related neo-
plasia receiving RFA and, therefore, we can be reason-
Table 3. Base case model results.
Outcome Treatment Comparator Incremental
Cost of EET (GB£)† 6317 0 6317
Cost of NDBE (GB£) 2735 41 2694
Cost of LGD (GB£) 1074 357 718
Cost of HGD (GB£) 70 8047 −7977
Cost of OAC (GB£) 573 1079 −506
Total cost (GB£) 10,769 9524 1246
Total QALYs 10.041 9.062 0.979
ICER (GB£) – – 1272
NMB  – – 0.92
†Cost of EET includes all associated costs (EMR, complications and drug costs).
EET: Endoscopic eradication therapy; HGD: High-grade dysplasia; ICER: Incremental cost–effectiveness ratio; LGD: Low-grade dysplasia; 
NDBE: No dysplasia Barrett’s esophagus; NMB: Net health benefit; OAC: Esophageal adenocarcinoma; QALY: Quality-adjusted life year. 
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Figure 2. Cohort Traces. (A) Cohort trace – treatment arm – number of people in each health state by time point. 
(B) Cohort trace – comparator – number of people in each health state by time point. 
es.: Esophagectomy; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; NDBE: Nondysplastic Barrett’s 
esophagus. 
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ably confident in this input value. For the results to 
cross the GB£20,000 threshold, the proportion of suc-
cessful treatment would have to decrease below 20% 
(base case: 92.6%). Such a large change in the success 
of RFA treatment is unlikely based on the abundance 
of recent publications from around the world showing 
dysplasia eradication rates of over 80% [21,35].
The second parameter is the HGD multiplier. The 
relationship between inputs when changing the multi-
plier is complex (see Figure 1A & B). When there are fewer 
people within HGD, there are proportionally more peo-
ple in the other three health states (NDBE, LGD, OAC). 
In order for the ICER to increase above GB£20,000, 
there would have to be less than half the proportion of 
patients that stay in the HGD health state each year in 
the natural history model. This would result in the other 
half of patients moving to the other health states because 
transition probabilities must add to 100% each cycle.
As with all models, the model structure reflects a 
simplification of reality. There may be some nuances in 
clinical practice that are not accounted for in the model 
structure which often reflects a lack of data to populate 
the necessary model parameters (such as, the distinction 
between early and late esophageal cancer and the fact 
10.2217/cer-2016-0089www.futuremedicine.com
Figure 3. Deterministic Sensitivity Analyses. (A) One-way sensitivity analysis – varying the proportion of patients with residual HGD 
after endoscopic eradication therapy. (B) One-way sensitivity analysis – HGD multiplier – varying the probability of patients staying in 
the HGD health state in each cycle. 
HGD: High-grade dysplasia; ICER: Incremental cost–effectiveness ratio.
Figure 4. Results of probabilistic sensitivity analysis. The blue dashed line represents the GB£20,000 cost–
effectiveness threshold. The purple dashed line represents the GB£30,000 threshold. Each data point on the graph 
shows the model results for cost and effect for one iteration of the probabilistic sensitivity analysis. Any iterations 
that fall below the cost–effectiveness threshold (dashed line) represent iterations can be considered cost-effective. 
QALY: Quality adjusted life year. 
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that current practice is variable, with a small proportion 
of patients receiving surgery when HGD is present [16] 
and the fact that some patients with OAC may present 
too late for surgery and will receive palliation only). In 
addition, some patients may regress to LGD after RFA 
and carry on treatment, not including this in the model 
should not impact on the results given that the patient 
incur the same costs and it is likely they experience a 
similar QOL as HGD patients. There is an assumption 
that all patients with HGD are fit to undergo repeated 
procedures for EET and also the patients with HGD 
in the surveillance arm are fit for regular surveillance 
until they develop cancer. We also assume that being 
in an endoscopic surveillance program results in cancer 
detected at an early stage that will result in the likelihood 
of curative intervention with surgery. This has been the 
basis for all the international guidance on BE surveil-
lance but recent data show that actually even though 
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cancer may be detected early there may not actually be 
a difference in survival in these patients [7]. However, 
the model aims to capture mean inputs for the average 
patient and find a balance between a model structure 
that is too complex or simple dependent, in part, on the 
data available with which to populate the model.
Due to a lack of data, many of the model inputs 
relied on previous literature, some of which was not 
based in the UK [26] or relied on expert clinical opin-
ion. For example, due to a lack of natural history data, 
the inputs used were from a previous model which 
calibrated the transition probabilities necessary for the 
model to the US annual incidence rates. The impact 
of varying these inputs on the model results was tested 
using univariate and PSA, discussed above.
Since April 2012, the NOGCA has been collecting 
data on patients with a new diagnosis of esophageal 
HGD in the UK. After 2 years of data collection, data 
on 930 cases of HGD were analyzed. The majority of 
these patients were offered EET and were managed 
nonsurgically, with EMR and RFA being used most 
frequently (67.5%). Only 6.3% of patients under-
went a surgical resection which in young patients, 
those with multifocal HGD with nodules that would 
risk EET being unsuccessful remains an alternative in 
the minority. The data showed that 26.2% of patients 
were managed by endoscopic surveillance alone. It 
must be pointed out that data collection for this audit 
commenced in April 2012 some months prior to the 
BSG guidelines in 2013 recommending EET as first-
line treatment for HGD patients. The data show that 
the proportion of HGD patients managed with sur-
veillance alone increased with age, from 12.6% for 
patients aged under 60 years to 43.2% in patients aged 
80 years or over (p < 0.001). This suggests that in some 
of the more elderly patients with comorbidity and other 
medical conditions precluding repeated endoscopic 
treatment surveillance until cancer developed was a 
more attractive option. Access to EET for patients with 
BE-related neoplasia is still limited to specialist cancer 
centers within the UK and, therefore, certain patients 
may have not had access, although with dissemination 
of national guidelines this is likely to change in the next 
round of audit.
Patients with BE-related neoplasia and HGD are at 
risk of developing OAC and suffer a poor prognosis 
once this occurs. Continuing advances in minimally 
invasive endoscopic therapy with advanced imaging 
to guide EMR followed by RFA mean that high rates 
of disease eradication are possible with a very good 
safety profile in these patients. International societies 
advise that the role of EET can be preferable to surgery 
or surveillance in these patients [3,18] and our results 
suggest that this minimally invasive approach might 
also be a cost-effective strategy and should help shape 
policy and resource planning locally.
Summary points
What is already known about this subject?
•	 Current clinical recommendations are to treat patients with Barrett’s esophagus and high-grade dysplasia 
(HGD) with endoscopic eradication therapy (EET) before esophageal cancer develops.
•	 The 2015 UK National Oesophago-Gastric Cancer Audit identified that over a quarter of patients with HGD 
were still managed with surveillance alone.
•	 Previous studies have investigated the cost–effectiveness of different treatment strategies for HGD. However, 
there were no available studies in the UK comparing EET with surveillance alone in patients with HGD.
What are the new findings?
•	 The base case economic model results estimate that EET is a cost-effective treatment strategy compared with 
surveillance alone for treating HGD patients in the UK.
•	 The additional quality-adjusted life years that patients gained offset the costs associated with EET treatment.
•	 Probabilistic sensitivity analysis showed a 61% probability of EET being cost-effective at a GB£20,000 threshold.
•	 A scenario analysis, in which the number of surveillance appointments in patients with HGD was 
increased from three to four per year, resulted in a cost saving and, therefore, a dominant incremental 
cost–effectiveness ratio.
How might it impact on clinical practice in the foreseeable future?
•	 International consensus supports EET for patients with Barrett’s esophagus-related neoplasia. In the UK, a 
significant proportion of patients with HGD still undergo surveillance alone. These data suggest that offering 
endoscopic therapy in those fit for treatment is an attractive and cost-effective approach.
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